Clinical Trials

We have initiated Phase 1 studies for our Treg therapy and our Teff biologic.

7101 Clinical Trial for RA

We have initiated a Phase 1 study to evaluate the safety and proof-of-mechanism of our lead Treg cell therapy candidate, SBT-77-7101, in patients with rheumatoid arthritis.

For more information, please see the 7101 RA study on ClinicalTrials.gov.

Learn More

5301 Clinical Trial

We are conducting a Phase 1 study of SBT-11-5301, our effector T cell-modulating biologic, in healthy participants.

For more information, please see the 5301 study on ClinicalTrials.gov.

Learn More